Results 131 to 140 of about 53,155 (262)

Targeting m6A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti‐PD‐L1 Efficacy in Intrahepatic Cholangiocarcinoma

Advanced Science, EarlyView.
The m6A reader YTHDF1 drives intrahepatic cholangiocarcinoma (ICC) progression by remodeling the tumor immune microenvironment. YTHDF1 promotes MDSC recruitment via activation of m6A‐FOSL2‐CXCL6/CXCR2 axis, thereby suppressing CD8+ T cell infiltration and function.
Li Luo, Ziqin Liu, Zimin Song, Dong Zhang, Cong Liang, Fei Fang, Kai Lei, Lina Wang, Weikang Chen, Shunli Shen, Ming Kuang, Xiaoxing Li, Jun Yu, Shiyan Wang, Lixia Xu   +14 more
wiley   +1 more source

Unexpected Long‐Term Disease Control in Lung Cancer With Sacral Metastases After Conventional Radiotherapy and Chemotherapy Despite Discontinuation of Maintenance Therapy: A Case Report

Clinical Case Reports
Novel treatments, including stereotactic body radiotherapy (SBRT), targeted therapies, and immune checkpoint inhibitors (ICIs), have improved the prognosis and outcomes of patients with metastatic lung cancer.
Reyhaneh Bayani, Mahdi Khakpour, Behnaz Jahanbin, Nima Mousavi Darzikolaee   +3 more
doaj   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy

Advanced Science, EarlyView.
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin, Hong Xiao, Shuai Fan, Kaimin Cai, Yanteng Xu, Xinwen Wang, Guanhong Chen, Chuandong Lang, Xinsheng Peng, Mingqiang Li, Yuhu Dai   +10 more
wiley   +1 more source

Interferon Alfa in the treatment of B-cell chronic lymphocytic leukemia [PDF]

, 1994
Adolf, D., Bergmann, L., Dietzfelbinger, H., Emmerich, B., Knauf, W. U., Langenmayer, Irmgard, Maubach, P. A., Mitrou, P. S., Nerl, C., Thiel, E., Ziegle-Heitbrock, H. W. L.   +10 more
core   +1 more source

CD28‐Targeted Enzyme‐Responsive Conformation‐Switching Peptide Self‐Assembly for Selective T‐Cell Acute Lymphoblastic Leukemia (T‐ALL) Therapy

Advanced Science, EarlyView.
We developed the enzyme‐responsive peptide SAp‐CD28 to selectively target CD28‐overexpressing T‐ALL cells. Following phosphatase‐mediated activation, SAp‐CD28 undergoes conformational switching and nanooligomerization, resulting in the disruption of CD28 downstream signaling.
Jun Li, Ziyu Jia, Dekun Li, Zhi‐Wen Hu, Yinghao Ding, Shengyi Zhang, Shengkun Tuo, Zhimou Yang, Huisheng Fu, Ling Wang, Man‐Di Wang   +10 more
wiley   +1 more source

Liquid Metal Nanotransformers for Drug‐Resistant Pan‐Cancer Therapy in Patient‐Derived Organoids

Advanced Science, EarlyView.
Pan‐cancer therapies are severely limited in drug‐resistance patients due to genetic mutations and other factors, resulting in poor therapeutic outcomes and constrained clinical benefit. Liquid metal nanotransformers, a new class of shape‐transformable nanomaterials capable of dramatic morphological changes, offer a promising physical strategy to ...
Xiaojie Yuan, Xuelin Wang, Zhongyao Chen, Shuo Wang, Weining Gao, Ziyi Chen, Runyang Li, Cheng Hao, Lei Zhang, Qiongqiong Zhang, Ke Zhang, Mei Yu, Qian Liu, Jingxuan Wang, Huiping Li, Simpkins Fiona, Jing Liu, Qiang Liu, Peng Liu, Yawei Hu   +19 more
wiley   +1 more source

A randomized study of docetaxel plus cisplatin versus paclitaxel plus cisplatin in previously untreated advanced non-small cell lung cancer

Chinese Journal of Lung Cancer, 2008
Background and objective Docetaxel is an active agent in the second-line treatment for non-small cell lung cancer (NSCLC), many clinical trials have demonstrated that it has similar efficacy to common first-line regimens for NSCLC. A randomized study was
Haiyong WANG, Yanfei GU, Xi LI, Xinjie YANG, Fanbin HU, Qunhui WANG, Shucai ZHANG, Jinghui ZHANG   +7 more
doaj  

Chemically Engineered L. reuteri Delivering αPD‐L1 and Gallium Ions via Metal‐Phenolic Networks Potentiate Anti‐Tumor Immunity and Ferroptosis

Advanced Science, EarlyView.
A multifaceted chemical strategy, integrating bacterial tropism, metal‐ion interference therapy, and immunotherapy, resulted in significant tumor regression in murine models. A pioneering paradigm for the design of biohybrid materials was established, highlighting how sophisticated chemical engineering of living systems can unlock new avenues for ...
Tingting Zhang, Mengyi Xu, Yan Zhang, Zhiwen Li, Danqing Song, Jing Pang, Ke Li, Yanxiang Wang   +7 more
wiley   +1 more source

Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells

Advanced Science, EarlyView.
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin, Dingqin Cai, Chunli Jian, Yaxian Qi, Linpeng Zheng, Qiao Yang, Longyao Zhang, Diangang Chen, Lingchen Li, Ping Cai, Lingyou Sun, Luping Zhang, Jianguo Sun   +12 more
wiley   +1 more source